PMV Pharmaceuticals, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

PMVP$1.22-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Condensed Consolidated Statements of Opera tions and Comprehensive Loss

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$18,400	$14,628	$35,841	$27,813
General and administrative	4,479	5,542	8,600	10,578
Total operating expenses	22,879	20,170	44,441	38,391
Loss from operations	(22,879)	(20,170)	(44,441)	(38,391)
Other income (expense):
Interest income, net	1,690	2,801	3,625	5,753
Other expense, net	(16)	(17)	(21)	(18)
Total other income	1,674	2,784	3,604	5,735
Loss before provision (benefit) for income taxes	(21,205)	(17,386)	(40,837)	(32,656)
Provision (benefit) for income taxes	5	(16,173)	(2,191)	(16,173)
Net loss	(21,210)	(1,213)	(38,646)	(16,483)
Unrealized (loss) on available for sale investments, net of tax	(61)	(61)	(123)	(380)
Foreign currency translation (loss) gain	(2)	5	6	(28)
Total other comprehensive loss	(63)	(56)	(117)	(408)
Total comprehensive loss	$(21,273)	$(1,269)	$(38,763)	$(16,891)
Net loss per share -- basic and diluted	$(0.41)	$(0.02)	$(0.74)	$(0.32)
Weighted-average common shares outstanding	52,010,827	51,478,751	51,981,607	51,462,307

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.